In a report released today, Matthew Biegler from Oppenheimer reiterated a Hold rating on Cartesian Therapeutics (RNAC – Research Report). The ...

Full Year 2024 Results Key Financial Results Revenue: US$38.9m (up 50% from ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

Cartesian Therapeutics, Inc., a biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its participation in several upcoming investor conferences in February ...

On Tuesday, H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a significant upside from the current trading price of $19.42.

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Cartesian Therapeutics (NASDAQ:RNAC), currently trading at $15.80, with a steady price target of $22.00. The stock has experienced ...

March 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases ...

FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Cartesian Therapeutics (NASDAQ:RNAC), currently trading at $15.80, with a steady price target of $22.00. The stock has experienced an ...